ATE236870T1 - Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE236870T1
ATE236870T1 AT99310223T AT99310223T ATE236870T1 AT E236870 T1 ATE236870 T1 AT E236870T1 AT 99310223 T AT99310223 T AT 99310223T AT 99310223 T AT99310223 T AT 99310223T AT E236870 T1 ATE236870 T1 AT E236870T1
Authority
AT
Austria
Prior art keywords
ethanones
nitrophenyl
dihydroxy
diseases
phenyl
Prior art date
Application number
AT99310223T
Other languages
English (en)
Inventor
Jan Benes
Da Silva Patricio Manue Soares
David Alexander Learmonth
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Application granted granted Critical
Publication of ATE236870T1 publication Critical patent/ATE236870T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99310223T 1998-12-18 1999-12-17 Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen ATE236870T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9827996A GB2344819A (en) 1998-12-18 1998-12-18 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones

Publications (1)

Publication Number Publication Date
ATE236870T1 true ATE236870T1 (de) 2003-04-15

Family

ID=10844561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99310223T ATE236870T1 (de) 1998-12-18 1999-12-17 Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen

Country Status (20)

Country Link
US (1) US6512136B1 (de)
EP (1) EP1010688B1 (de)
CN (1) CN1173926C (de)
AR (1) AR021893A1 (de)
AT (1) ATE236870T1 (de)
AU (1) AU754113B2 (de)
BR (1) BR9908084B1 (de)
CA (1) CA2292968C (de)
CZ (1) CZ297919B6 (de)
DE (1) DE69906671T2 (de)
DK (1) DK1010688T3 (de)
ES (1) ES2197583T3 (de)
GB (1) GB2344819A (de)
HU (1) HU226396B1 (de)
PL (1) PL193998B1 (de)
PT (1) PT1010688E (de)
RU (1) RU2232748C2 (de)
SI (1) SI1010688T1 (de)
TR (1) TR200003019T1 (de)
WO (1) WO2000037423A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015228D0 (en) * 2000-06-21 2000-08-16 Portela & Ca Sa Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
GB2377934B (en) * 2001-07-25 2005-01-12 Portela & Ca Sa Method for the nitration of phenolic compounds
FI20012242A0 (fi) * 2001-11-19 2001-11-19 Orion Corp Uudet farmaseuttiset yhdisteet
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
MY148644A (en) * 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1764095A1 (de) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Neue Nitrocatecholderivate mit Selectin-Ligand-Activität
US20090012177A1 (en) * 2006-03-23 2009-01-08 Rahim Shafa Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs
EP1845097A1 (de) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazolderivate als COMT Inihibitoren
HRP20120479T1 (hr) 2006-06-28 2012-07-31 Chelsea@Therapeutics@Inc Farmaceutski sastavi sa droksidopom
DK2481410T3 (en) * 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
AU2008226541B2 (en) 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
ES2431570T3 (es) 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
EP2234608A2 (de) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzymhemmer mit metallbindenden teilen in kombination mit targeting-teilen
EP2259777A2 (de) * 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmazeutische zusammensetzung für schwer lösliche arzneimittel
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
PT2413913T (pt) * 2009-04-01 2022-06-09 Bial Portela & Ca Sa Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
TW201107303A (en) * 2009-05-27 2011-03-01 Sanofi Aventis Process for the production of benzofurans
JP5774610B2 (ja) 2010-03-04 2015-09-09 オリオン コーポレーション パーキンソン病の治療方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状(姿勢反射異常)の治療剤
US9126988B2 (en) 2011-12-13 2015-09-08 Bial—Portela & Ca, S.A. Intermediate for preparing a catechol-O-methyltransferase inhibitor
SG11201404496PA (en) 2012-01-31 2014-12-30 Lundbeck Na Ltd Improving postural stability administering droxidopa
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
WO2014147464A2 (en) * 2013-03-20 2014-09-25 Ra Chem Pharma Limited Novel process for the preparation of tolcapone
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN111902386A (zh) * 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 作为fto抑制剂的苯基甲酮衍生物
WO2020234275A1 (en) * 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
RU2004536C1 (ru) * 1991-05-30 1993-12-15 Новосибирский институт органической химии СО РАН Способ получени мускус-кетона

Also Published As

Publication number Publication date
SI1010688T1 (en) 2003-10-31
US6512136B1 (en) 2003-01-28
CN1173926C (zh) 2004-11-03
CZ20003018A3 (cs) 2000-12-13
DE69906671T2 (de) 2004-03-04
BR9908084A (pt) 2000-10-24
HUP0100786A3 (en) 2002-12-28
AU754113B2 (en) 2002-11-07
EP1010688B1 (de) 2003-04-09
CA2292968C (en) 2009-05-19
WO2000037423A1 (en) 2000-06-29
GB9827996D0 (en) 1999-02-10
TR200003019T1 (tr) 2001-02-21
CZ297919B6 (cs) 2007-04-25
PL342542A1 (en) 2001-06-18
DK1010688T3 (da) 2003-08-04
PL193998B1 (pl) 2007-04-30
CN1296471A (zh) 2001-05-23
AU1873100A (en) 2000-07-12
RU2232748C2 (ru) 2004-07-20
ES2197583T3 (es) 2004-01-01
HUP0100786A2 (hu) 2001-08-28
BR9908084B1 (pt) 2009-12-01
AR021893A1 (es) 2002-08-07
CA2292968A1 (en) 2000-06-18
GB2344819A (en) 2000-06-21
EP1010688A1 (de) 2000-06-21
PT1010688E (pt) 2003-08-29
HU226396B1 (en) 2008-11-28
DE69906671D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE69913520D1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE122006000035I1 (de) D2-Agonist enthaltendes transdermales Therapeutisches System zur Behandlung des Parkinson-syndroms und Berfahren zu seiner Herstellung
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69715358D1 (de) Topische Zusammensetzung enhaltend Pulver aus Safflorsamen zur Behandlung von rheumatoiden Arthritis Krankheiten und Menopause
DE69526390D1 (de) Kugelförmige Aktivkohle zur Behandlung von Stoma-peripherer Entzündung
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE58904683D1 (de) Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE316529T1 (de) Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns)
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1010688

Country of ref document: EP

REN Ceased due to non-payment of the annual fee